Scott L Childs Email & Phone Number

• Renovo is a privately held boutique pharmacetutical company specializing in the commercialization of pharmaceutical cocrystals. Renovo identifies new, patentable, solid forms of active pharmaceutical ingredients (APIs).
• Responsibilities at Renovo include planning, staffing, laboratory management and coordinating all scientific, accounting, legal and business development activities
• Received an SBIR Phase I Grant from the National Science Foundationin 2013 to study the integration of highly soluble cocrystals into supersaturating drug delivery systems
• Experienced with equipment automation and systems integration. Designed and implemented the automation of X-ray powder diffraction and Raman spectroscopy instruments to collect high-throughput data. This included.
• Designed and manufactured a complete high-throughput solid form screening platform based take-apart reactor blocks with integrated stirring and sonication capabilities. Crystallization conditions include wet or dry.
• Mentored direct reports to increase their capabilities and expertise; all direct reports were able to directly leverage high value skills gained at Renovo in their subsequent industry positions

Lafayette, IN, US

• Formed Triclinic Labs along with top level management from SSCI to continue the successful business strategy originated at SSCI. Triclinic Labs is a contract research organization specializing in solid-state.
• Report directly to COO performing projects and reporting new R&D to be used in sales talks
• Continuous R&D has maintained the leading role in cocrystals established at SSCI
• Procured, directed and carried out client projects in crystal form screening and characterization

Amplio Pharma is an entrepreneurial startup funded by private capital that creates new intellectual property using cocrystal technology.

Atlanta, GA, US

A faculty equivalent appointment in the Chemistry department (non-compensated) to facilitate academic collaborations both internal and external to Emory. Collaborations with ten researchers at eight institutions have resulted in thirteen academic publications in peer-reviewed journals.

Verona, VR, IT

The change in corporate culture and R&D priorities that followed the purchase of SSCI by Aptuit led to myself and the key top level management from SSCI leaving to start Triclinic. This consulting position was negotiated in order to smooth the transition. In this consulting role I completed projects, drafted patents and submitted research papers on behalf.

Albany, NY, US

• Lead scientist at SSCI charged with investigating cocrystallization of pharmaceuticals in 2002 when the field was at it's infancy.
• From 2002 to 2008 SSCI became a leader in the field of pharmaceutical cocrystal under Dr. Childs' direction
• Discovered a previously unknown class of cocrystals containing the hydrochloride salt of an API plus an additional non-ionized coformer
• Lead scientist in the implementation and validation of a Symyx crystallization system for polymorph, salt and cocrystal screening
• Developed successful hotstage (modified Kofler) techniques and designed and built customized equipment to perform the screening
• Academic collaborations yielded significant advancements in screening approaches based on slurry transformation, wet milling, and phase-diagram directed solvent selection

• Design Science was formed to pursue commercial applications based on cocrystals
• Operations established at the EmTechBio start-up incubator facility at Emory University
• Acquired in January, 2002, becoming a wholly-owned subsidiary of SSCI, Inc.

Doctor Of Philosophy (Phd), Chemistry

Bachelor Of Arts (B.A.), Chemistry And Biology